Why genetic classification matters in X-linked retinoschisis

X-linked retinoschisis (XLRS) is linked to changes in the RS1 gene. As gene-based therapies for retinal diseases move forward, identifying whether a person’s RS1 variant is truly disease-causing becomes increasingly important. Genetic test reports can influence diagnosis, family discussions, research participation, and eligibility assessments for studies developing potential treatments.

A 2026 publication in Human Genetics describes a major step toward more consistent interpretation of RS1 variants. The work was led by the Clinical Genome Resource (ClinGen) X-Linked Inherited Retinal Diseases Variant Curation Expert Panel (XLRD VCEP), a group that brings together clinician-scientists, molecular biologists, and geneticists. Their goal was to create RS1-specific rules for deciding how much confidence can be placed in a variant’s clinical significance.

From broad guidelines to RS1-specific rules

Genetic variants are commonly classified using the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) framework. Under this approach, variants may be described as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign.

However, broad rules do not always capture the details that matter for one particular gene or condition. Evidence that is highly informative in one disease may be less meaningful in another. The ClinGen panel therefore adapted ACMG/AMP guidance specifically for RS1, aiming for a framework that is both systematic and conservative.

“Conservative” is particularly important when a result may affect decisions about clinical research or emerging gene-based treatments. A variant should not be labeled disease-causing without enough evidence, but uncertainty should also be reduced when strong evidence exists.

The RS1-specific process uses 28 evidence codes across several key areas:

  • Phenotype evidence: whether a person’s clinical features are consistent with RS1-related XLRS.
  • Population evidence: how often a variant appears in population datasets.
  • Computational assessment: whether prediction tools suggest that a genetic change may affect the gene or its protein product.
  • Functional evidence: results from laboratory studies assessing the impact of a variant.
  • Segregation evidence: whether a variant tracks with disease within families.

Each code can be applied at one of four strengths: very strong, strong, moderate, or supporting. This structured approach helps curators weigh different types of evidence rather than relying on a single observation or test.

Pilot curation changed the interpretation of several variants

To test the new rules, the panel evaluated 54 RS1 variants. Forty-seven of these had entries in ClinVar, a widely used public archive of relationships between genetic variants and health conditions.

The pilot exercise showed that applying gene-specific criteria can meaningfully change variant interpretation. A total of 21 variants were reclassified. Among the changes, two variants previously called likely pathogenic and one previously called likely benign were moved to the category of variant of uncertain significance (VUS). This means the available evidence was not sufficient to support the earlier level of confidence under the newly tailored RS1 framework.

The panel also reclassified four previously unclassified variants as pathogenic, likely pathogenic, or likely benign. Other updates addressed conflicting interpretations or multiple classifications already associated with variants in ClinVar.

These results illustrate an important point for patients and families: a genetic classification is evidence-based, but it is not necessarily permanent. As expert groups develop better disease-specific methods and evaluate new data, a variant’s classification may be refined.

Implications for treatment development and trial readiness

The publication directly connects accurate variant interpretation with the development of gene-based therapies for retinal disease. For RS1-related XLRS, clear classification can help distinguish people who have a disease-causing RS1 variant from those whose genetic result remains uncertain or is likely unrelated to disease.

This distinction matters when studies define who can be enrolled. It can also support more consistent communication among diagnostic laboratories, clinicians, researchers, and families. When different laboratories reach different conclusions about the same variant, it can create confusion; expert-panel curation provides a transparent method for resolving or clarifying those differences.

Importantly, the study does not suggest that every RS1 variant can now be definitively classified. Instead, it provides a more rigorous pathway for evaluating evidence and identifying where additional clinical, family-based, population, or laboratory data are needed.

Building a stronger foundation for the future

The RS1-specific ACMG/AMP criteria represent a practical advance for the XLRS community. By testing the framework on real-world variants and updating classifications in ClinVar, the ClinGen XLRD VCEP has created a more consistent foundation for future curation.

As gene-based therapeutic research continues, robust genetic interpretation will remain central to identifying appropriate study populations and understanding the genetic landscape of XLRS. The pilot project also demonstrates the value of ongoing expert review: better frameworks, shared evidence, and careful re-evaluation can turn uncertain genetic findings into clearer answers over time.